News

ATTR-CM is progressive, underdiagnosed, and hits our community hardest. Here's what you need to know.Morgan Freeman has played God, not once, but twice on screen,…

AbstractLight chain (AL) amyloidosis is a systemic disorder caused by plasma cell dyscrasia, with cardiac involvement being the primary determinant of prognosis.…

The injectable therapy eplontersen failed to show a significant benefit over a placebo at reducing cardiovascular events and related deaths in a Phase 3 clinical…

AbstractCardiovascular amyloidosis affects the health of a significant proportion of the global population. These diseases are characterised by the deposition of…

AbstractBackgroundCardiac amyloidosis (CA) is an infiltrative cardiomyopathy associated with adverse outcomes. Quantification of myocardial amyloid burden is…

What's going on here?BofA Securities just got more cautious on Alnylam’s heart-drug story, trimming its peak sales view to $11.8 billion and cutting its price…

Anselamimab therapy is associated with improved all-cause mortality (ACM) and reduced cardiovascular hospitalizations (CVHs) in patients with kappa immunoglobulin…

ExtractTransthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure with a complex and heterogeneous disease course. Accurate…

AbstractBackground: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy and an increasingly recognized cause of heart failure. With…

The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market was valued at USD 5.85 billion in 2025 and is projected to reach USD 64.09 billion by 2033, growing…